Covid-19 con­tin­ues to be­fud­dle Big Phar­ma as Ab­b­Vie ax­es PhI of an oral drug

In the fight against Covid-19, Ab­b­Vie’s ap­proved prod­ucts and in­ves­ti­ga­tion­al as­sets have run in­to mul­ti­ple hur­dles.

The lat­est is a Phase I axe, qui­et­ly re­vealed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.